New study identifies genetic variant that could help reduce need for liver transplants

April 02, 2019

A new study from The Westmead Institute for Medical Research has identified a genetic variant associated with liver fibrosis (scarring) in chronic hepatitis C patients. This finding is a step toward reducing the number of patients requiring liver transplants.

Researchers studied the role and mechanisms of a genetic variation in the MICA gene, a gene that is induced when cells are damaged.

The research team were able to show that, in 1,689 patients with chronic hepatitis C, the MICA gene variant rs2596542 is associated with the progression and severity of liver fibrosis.

They believe this occurs because rs2596542 triggers an immune response that increases the rate of liver fibrosis in patients with chronic hepatitis C infection.

First author of the study, Dr Rasha El Sharkawy said, "Understanding how and why liver fibrosis occurs is crucial for preventing health complications in those at risk.

"Chronic hepatitis C, liver fibrosis and hepatocellular carcinoma (or HCC - the most common form of primary liver cancer) are all serious conditions that are closely linked.

"Chronic hepatitis C is a major risk factor for liver cirrhosis (advanced liver fibrosis), and a leading cause of HCC in Australia. Liver scarring and chronic hepatitis C are both conditions that can lead to a liver transplant.

"The rate of fibrosis differs from person to person, so understanding the genetics behind liver fibrosis is critical for prevention.

"Now that we have identified a genetic variant associated with liver fibrosis in people with chronic hepatitis C, we can work towards targeting this variant to identify which patients are at greater risk of developing liver fibrosis, as well as creating better preventative measures and new treatments."

Currently, there are no approved treatments to reduce fibrosis in the liver. Liver transplantation is the only 'cure' for those with end-stage liver disease.

"Each year an estimated 339,000 people die globally from hepatitis C, mostly from cirrhosis and HCC," Dr El Sharkawy said.

"While some patients are eligible for a liver transplant to 'treat' complications, there are far more patients than there are donors, and not all patients are suitable for a transplant.

"Preventing the progression of fibrosis could reduce the number of patients who require a liver transplant.

"By identifying which patients are at a greater risk of fibrosis, we can potentially prevent complications of fibrosis before they occur.

"We can now also investigate the risk variant as a potential target for future treatments, reducing the overall number of patients living with liver complications."

The research paper was published in Scientific Reports: https://www.nature.com/articles/s41598-018-35736-2
-end-
The research was led by Professor Jacob George and Associate Professor Mohammed Eslam.

Dr Rasha El Sharkawy is affiliated with The Westmead Institute for Medical Research and the University of Sydney.

Professor Jacob George is affiliated with The Westmead Institute for Medical Research, the University of Sydney and Westmead Hospital.

Associate Professor Mohammed Eslam is associated with The Westmead Institute for Medical Research and the University of Sydney.

Westmead Institute for Medical Research

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.